可药性
药物发现
计算生物学
溴尿嘧啶
癌症
药品
鉴定(生物学)
药物开发
医学
癌基因
药理学
生物信息学
生物
癌症研究
遗传学
基因
表观遗传学
植物
细胞周期
作者
Muzammal Hussain,Yang Zhou,Yu Song,H. M. Adnan Hameed,Hao Jiang,Yaoquan Tu,Jiancun Zhang
标识
DOI:10.1080/14728222.2018.1406921
摘要
INTRODUCTION: ATAD2 protein is an emerging oncogene that has strongly been linked to the etiology of multiple advanced human cancers. Therapeutically, despite the fact that genetic suppression/knockdown studies have validated it as a compelling drug target for future therapeutic development, recent druggability assessment data suggest that direct targeting of ATAD2's bromodomain (BRD) may be a very challenging task. ATAD2's BRD has been predicted as a 'difficult to drug' or 'least druggable' target due to the concern that its binding pocket, and the areas around it, seem to be unfeasible for ligand binding. Areas covered: In this review, after shedding light on the multifaceted roles of ATAD2 in normal physiology as well as in cancer-etiology, we discuss technical challenges rendered by ATAD2's BRD active site and the recent drug discovery efforts to find small molecule inhibitors against it. Expert opinion: The identification of a novel low-nanomolar semi-permeable chemical probe against ATAD2's BRD by recent drug discovery campaign has demonstrated it to be a pharmacologically tractable target. Nevertheless, the development of high quality bioavailable inhibitors against ATAD2 is still a pending task. Moreover, ATAD2 may also potentially be utilized as a promising target for future development of RNAi-based therapy to treat cancers.
科研通智能强力驱动
Strongly Powered by AbleSci AI